Following the successful release of the LYMA Laser PRO in the United States last year, resulting in a reported $48 million in revenue and $7 million EBITDA for the year ending 31 December 2025, pioneering British brand, LYMA, announced its additional U.S. expansion plans in a press April 6 press release.
According to the press release, the expansion will include a stand-alone U.S. website and dedicated concierge service with new instalment payment plans including flexible payment options and HSA and FSA payments for eligible customers, plus new retail partnerships including Bloomingdale's launching this summer.
Related: 5 Ways to Take Advantage of Flexible Patient Payment Options [Survey Results]
The new U.S. site goes live with structural improvements for customers; USD pricing with no foreign exchange friction, faster delivery fulfilment, a dedicated U.S. concierge team operating across U.S. time zones and flexible payment options.
LYMA has appointed its first C Suite hire in the States, U.S. Growth Officer Nicole Fein, to lead the B2B and professional channel, wholesale and distributor accounts. Launching firstly in New York and expanding to other key cities throughout the year, LYMA's physician referral programme gives plastic surgeons, aesthetic practitioners and medical spa owners two partnership routes. LYMA launches into a brand-new category with the world's first four-dimensional gut formula next month
In February 2025, LYMA published landmark research in the Aesthetic Surgery Journal Open Forum — the first peer-reviewed evidence of multi-gene longevity activation from a consumer device.
Key science headlines include:
- 45 genes activated by LYMA Laser vs. 1 gene by LED, in RNA sequencing analysis
- 6x increase in SIRT1 — the longevity gene — expression
- 32x increase in TXNRD1, responsible for oxidative stress protection
- 103% increase in skin elasticity in 30 days — a clinical record for any at-home device
- 46% reduction in pigmentation over six weeks
- 40% complete wound healing with LYMA Laser vs. 0% in the control group
